ETD001 

ETD001 is a long-acting ENaC inhibitor, with an IC₅₀ of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis^[1][2].

1045.93

C₄₁H₅₇F₆N₉O₁₆

2227484-71-9

OC(C(F)(F)F)=O.[O-]C(C(F)(F)F)=O.CC[N+](C1=C2)=C(CNC(C3=C(N)N=C(NC=C4)C4=N3)=O)N(CC)C1=CC=C2C(N5CCC(CC5)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Henry Danahay, et al. Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis. Eur J Med Chem. 2025 Jan 15:282:117040.  [Content Brief]

  [2]. Henry Danahay, et al. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. J Cyst Fibros. 2024 Jun 7:S1569-1993(24)00081-X.  [Content Brief]